Signaling Pathways Regulating TC21-induced Tumorigenesis
Overview
Affiliations
TC21(R-Ras2), a Ras-related GTPase with transforming potential similar to H-, K- and N-Ras, is implicated in the pathogenesis of human cancers. Transforming growth factor beta (TGF-beta), a cytokine that plays a significant role in modulating tumorigenesis, normally prevents uncontrolled cell proliferation but paradoxically induces proliferation in H-Ras-transformed cancer cells. Although TC21 activates some pathways that mediate cellular transformation by the classical Ras proteins, the mechanisms through which TC21 induces tumor formation and how TGF-beta regulates TC21 transformed cells is not known. To better understand the role of TC21 in cancer progression, we overexpressed an activated G23V mutant of TC21 in a nontumorigenic murine mammary epithelial (EpH4) cell line. Mutant TC21-expressing cells were significantly more oncogenic than cells expressing activated G12V H-Ras both in vivo and in vitro. TC21-induced transformation and proliferation required activation of p38 MAPK, mTOR (the mammalian target of rapamycin), and phosphoinositide 3-kinase but not Akt/PKB. Transformation by TC21 rendered EpH4 cells insensitive to the growth inhibitory effects of TGF-beta, and the soft agar growth of these cells was increased upon TGF-beta stimulation. Despite losing responsiveness to TGF-beta-mediated growth inhibition, both Smad-dependent and independent pathways remained intact in TC21-transformed cells. Thus, overexpression of active TC21 in EpH4 cells induces tumorigenicity through the phosphoinositide 3-kinase, p38 MAPK, and mTOR pathways, and these cells lose their sensitivity to the normal growth inhibitory role of TGF-beta.
Weber S, Brossier N, Prechtl A, Barnes S, Wilson L, Brosius S Cell Commun Signal. 2021; 19(1):95.
PMID: 34530870 PMC: 8447793. DOI: 10.1186/s12964-021-00773-4.
Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.
Capri Y, Flex E, Krumbach O, Carpentieri G, Cecchetti S, Lissewski C Am J Hum Genet. 2019; 104(6):1223-1232.
PMID: 31130282 PMC: 6562003. DOI: 10.1016/j.ajhg.2019.04.013.
Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.
Michael J, Goldfinger L Semin Cancer Biol. 2017; 54:121-130.
PMID: 29203271 PMC: 5984110. DOI: 10.1016/j.semcancer.2017.11.021.
Limoge M, Safina A, Truskinovsky A, Aljahdali I, Zonneville J, Gruevski A Oncotarget. 2017; 8(37):61969-61981.
PMID: 28977919 PMC: 5617479. DOI: 10.18632/oncotarget.18755.
SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation.
Zhang X, Spiegelman N, Nelson O, Jing H, Lin H Elife. 2017; 6.
PMID: 28406396 PMC: 5391209. DOI: 10.7554/eLife.25158.